Immutep Limited IMMP
3.56 USD +0.10 (+2.89%)
At closeNov 11, 2026, 4:00 PM EST
3.56 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
3.43 Day range 3.74
2.66 52-week range 70.60
- YTD
- +24.48%
- 1 year
- +100.00%
News
benzinga.com Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial Immutep shares rise after reporting promising Phase 2 sarcoma trial results for efti and securing a key U.S. patent valid through 2038.
globenewswire.com Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced…
benzinga.com Immutep Reports Encouraging EFTISARC-NEO Phase II Sarcoma Survival Data; Efti + KEYTRUDA + Radiotherapy Shows 81.1% 12-Month DFS, 94.1% LRFS And 86.2% DMFS In 38 Patients First survival data from EFTISARC-NEO, released in CTOS 2026 Abstract, demonstrate encouraging preliminary long-term outcomes in patients with resectable soft tissue sarcoma (STS).With a median…
globenewswire.com Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) today announced the release of an abstract reporting interim disease-free survival data and…
globenewswire.com IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses SYDNEY, AUSTRALIA, Nov. 08, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune…
globenewswire.com Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026 SYDNEY, AUSTRALIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune…
benzinga.com Immutep Refocuses Efti Development On HNSCC, Soft Tissue Sarcoma; New Trial Starts Targeted For H2 2027 Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials…
benzinga.com Immutep Receives Cash Payment Of €1.36M From French Government Under Tax Incentive Program Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received a cash…
benzinga.com Immutep Presents ePoster At European Society For Medical Oncology Congress 2026 For Its Eftilagimod Alfa In Combination With KEYTRUDA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced health-related quality of life
defenseworld.net Prima BioMed (NASDAQ:IMMP) Share Price Crosses Below Fifty Day Moving Average – What’s Next? Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report)'s share price crossed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $6.08 and traded as…
benzinga.com Immutep Receives A$652,248 Grant From Monash University Under Australian Research Council's Linkage Projects Scheme For Research Collaboration Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce- benzinga.com Immutep Receives A$856,669 Cash Rebate From Australian Federal Government’s R&D Tax Incentive Program Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash
globenewswire.com Immutep Receives ~A$0.86 Million R&D Tax Incentive SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune…
benzinga.com Immutep Changes ADS Ratio From One ADS Representing 10 Shares To One ADS Representing 200 Shares, Effective September 28 With effect from the commencement of trading on the Nasdaq Global Market on 28 September 2026 (US Eastern time), the ADS ratio will change from one (1) ADS representing ten (10) ordinary shares to…
defenseworld.net Short Interest in Prima BioMed Ltd (NASDAQ:IMMP) Decreases By 36.4% Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 760,586…
defenseworld.net Prima BioMed (NASDAQ:IMMP) Stock Crosses Above 50 Day Moving Average – Should You Sell? Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report) crossed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.40 and traded as high as $0.41. Prima…
globenewswire.com Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune…
benzinga.com Immutep Announces Positive Update For Phase I Trial Evaluation Of Eftilagimod Alfa Key Results from INSIGHT-003 – Data Cutoff – 27 March 2026Approximately 92% of patients enrolled in INSIGHT-003 had no or low PD-L1 expression (Tumour Proportion Score: TPS <50%), representing a…
globenewswire.com Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004 SYDNEY, AUSTRALIA, July 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced a…
prnewswire.com Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP LOS ANGELES, July 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b)…
gurufocus.com IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm [url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited (âImmute
businesswire.com IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm LOS ANGELES--(BUSINESS WIRE)---- $IMMP--IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm.
feeds.newsfilecorp.com Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - July 2, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
globenewswire.com IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm LOS ANGELES, July 02, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited (“Immutep” or…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP NEW YORK, July 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP). Such investors are…
globenewswire.com IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP) investors of…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP). Such investors are…
feeds.newsfilecorp.com Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - June 30, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
globenewswire.com Portnoy Law Firm Announces Class Action on Behalf of Immutep Limited Investors LOS ANGELES, June 30, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immutep Limited, (“Immutep” or the "Company") (NASDAQ: IMMP) investors of a class action on behalf of investors that bought…- benzinga.com Immutep To Present Interim Phase I Data For IMP761 At EULAR 2026 First-in-human Phase I study met its primary endpoint, demonstrating favourable safety and tolerability in healthy volunteers in the single ascending dose part of the studyPhase I data demonstrate…
- benzinga.com Immutep Receives Nasdaq Noncompliance Notice, Gets Time Through Oct. 26 To Regain Compliance Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), advises that it has received a written notification from The Nasdaq Stock Market LLC (Nasdaq) regarding non-compliance with the…
benzinga.com Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings US stocks rise, Nasdaq up 200 points; Tech shares lead gains. Morgan Stanley beats estimates. Allbirds up 349%, Snap up 6%. Oil rises 0.7%, gold up 0.1%.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Immutep Gets FDA Boost For Lead Cancer Drug, Stock Doubles Immutep stock jumps after FDA orphan drug tag for eftilagimod alfa, even as halted Phase 3 trial and mixed analyst views weigh on outlook.
benzinga.com Dow Gains 100 Points; Bank of America Earnings Top Views US stocks up on Wed, Dow +0.22%, NASDAQ +0.37%, S&P 500 +0.28%. Bank of America beats Q1 earnings. Allbirds Inc. shares soar 323%.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Why NN Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket NN Inc. (NNBR) rose in pre-market trading after announcing expected sales growth and raising full-year guidance. Other gainers include NICM, AGAE, IMMP, LIMN, CIIT, MLSS, LAES, GBR, and STNE. Losers…
benzinga.com Immutep Announces Update From Placebo-Controlled, Double-Blind First-In-Human Phase I Study In Healthy Participants Evaluating IMP761 For Autoimmune Diseases Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levelsIMP761 data and Phase I results will be presented at the EULAR…
benzinga.com Immutep Stock Tanks After Futility Analysis Ends Key Lung Cancer Trial Early Immutep announced the discontinuation of the TACTI-004 Phase 3 trial. The CEO expresses disappointment. Stock down 80.62% to $0.53.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com This Karman Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Wall Street analysts changed outlook on top names. See ratings page for upgrades, downgrades, and initiations. Analysts recommend H2O, KRMN, GNSS, WCN, and WM stocks.
benzinga.com Crude Oil Gains Over 1%; VEON Shares Spike Higher US stocks mostly lower, Nasdaq drops 0.71%, Dow up 0.03%. Utilities up 1.2%, communication services down 1.2%. PCE index rose 2.8%, GDP up 0.7%.
benzinga.com Dow Gains Over 300 Points; US GDP Growth Revised Lower In Q4 U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. U.S. stocks rally as Dow jumps 300+ points on strong morning trading. GDP growth slows in Q4. Energy…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com This EverCommerce Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Wall Street analysts change outlook on top companies. See analyst rating changes and their thoughts on EVCM stock before buying.
benzinga.com Baird Downgrades Immutep to Neutral, Lowers Price Target to $1 Baird analyst Joel Beatty downgrades Immutep (NASDAQ:IMMP) from Outperform to Neutral and lowers the price target from $7 to $1.
benzinga.com Why Oncology Institute Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket The Oncology Institute (TOI) stock rose in pre-market trading after reporting better-than-expected financial results. Other gainers include ISPC, PAYP, and EONR.
benzinga.com Citizens Initiates Coverage On Immutep with Market Outperform Rating, Announces Price Target of $10 Citizens analyst Reni J. Benjamin initiates coverage on Immutep (NASDAQ:IMMP) with a Market Outperform rating and announces Price Target of $10.- benzinga.com Citizens Initiates Coverage On Immutep with Market Outperform Rating, Announces Price Target of $6 Citizens analyst Reni J. Benjamin initiates coverage on Immutep (NASDAQ:IMMP) with a Market Outperform rating and announces Price Target of $6.
- benzinga.com Immutep Achieves 50% Participant Enrollment Target In TACTI-004 Phase III Study Evaluating Eftilagimod Alfa In Combination With Merck's Anti-PD-1 Therapy Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has achieved 50% of the patient…